Vertex Looks To Triple Combos For CF After Doublet Success
Executive Summary
Top-line results from two Phase III studies indicate Vertex’s potential new combination cystic fibrosis therapy, tezacaftor plus ivacaftor, is effective and well tolerated in certain cystic fibrosis patients, and could become the backbone of a triple combination therapy for a wider patient group.
You may also be interested in...
Celtaxsys To Hash Out Phase III Cystic Fibrosis Endpoints With US FDA
Private start-up's acebilustat failed to improve lung function in Phase II, but the anti-inflammatory showed large numerical reductions in pulmonary exacerbations, which can be fatal.
Vertex Strikes Novel Reimbursement Deal For Cystic Fibrosis Drugs in Ireland
A novel deal struck by Vertex and the Irish authorities will ensure reimbursement for the company’s cystic fibrosis drugs, Orkambi and Kalydeco, not only for current uses but for newly approved populations – and any new products for the same uses.
Vanda's Licenses CFTR Modulators From UCSF, But Not For Cystic Fibrosis
Intellectual property licensed from UCSF focuses on non-mutated, wild-type CFTR activators and inhibitors, thought to offer potential in ophthalmic, renal and gastrointestinal indications.